Immunocore reported early data for a combination of the T cell engager brenetafusp plus Kimmtrak in uveal melanoma at SITC 26. The company said it is seeing encouraging survival signals at two years in a subset of patients receiving the doublet. Even before randomized evidence, dual-engager strategies are shaping trial design, particularly in solid tumors where single-agent T cell engagers have shown limited or transient activity. The update may also affect how sponsors structure next-step combination trials—such as adding standard-of-care or partnering with checkpoint blockade. For industry watchers, the headline is not just the early survival estimate, but the ongoing clinical push to improve depth and duration of response by combining complementary immune-engagement mechanisms.